The Jazz Piccolo Study (Piccolo means “little one” in Italian) is investigating the safety and effectiveness of cannabidiol (or CBD oral solution) in infants (2 years of age and younger) with Tuberous Sclerosis Complex (TSC), Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) who experience inadequately controlled seizures.
What do I need to know about the study?
The Jazz Piccolo Study will involve up to 10 visits to a study clinic and 12 telephone
calls including a:
- 4-week screening/baseline period
- 52-week treatment period
- 10-day taper following completion of the 52-week treatment regiment
- 4-week safety/follow-up period
Children who are eligible and participate in the Jazz Piccolo Study will receive the investigational drug, as well as study-related visits, tests and assessments, at no cost. Participants can stop taking part in the clinical trial at any time without giving a reason. Caregivers of participants may also be reimbursed for some study-related expenses, such as costs associated with travel and hotels.
For more information on the jazz piccolo study, and to see if your child qualifies, please visit: www.Jazzpiccolostudy.com